Core Viewpoint - The article discusses the rising obesity rates in China and the impact of GLP-1 receptor agonists, particularly semaglutide, on weight management and the challenges associated with medication adherence and weight maintenance after discontinuation [2][3]. Group 1: Obesity Statistics in China - China has the highest number of overweight and obese individuals globally, with over 50% of the adult population classified as overweight or obese, totaling approximately 532 million people, including nearly 100 million who are obese [2]. - A 2020 study predicts that by 2030, the number of overweight adults in China will reach 540 million, and the number of obese individuals will increase to 150 million, representing a 2.8-fold and 7.5-fold increase from 2000, respectively [2]. Group 2: Medication Adherence and Discontinuation - Research indicates that semaglutide has the highest adherence rate among weight loss medications, with 63% of patients still using it after three months, 56% after six months, and 40% after one year [5]. - Common reasons for discontinuation include side effects such as nausea, diarrhea, and gastrointestinal issues, which can lead to a significant percentage of patients stopping the medication [9][10]. Group 3: Effects of Discontinuation - A clinical trial showed that participants who stopped semaglutide after a 20-week treatment regained an average of 6.9% of their body weight, while those who continued lost an additional 7.9% [6]. - An observational study found that 18% of patients regained their lost weight after one year of stopping semaglutide, with 26% regaining more than 25% of their lost weight [6]. Group 4: Reasons for Stopping Medication - Patients may stop using semaglutide due to side effects, reaching a weight loss plateau, or achieving their target weight [11][13][14]. - The lack of insurance coverage for semaglutide when used for weight loss also contributes to discontinuation [12]. Group 5: Recommendations for Discontinuation - Gradually reducing the dosage of GLP-1 receptor agonists is recommended to minimize rebound hunger and manage weight effectively after stopping the medication [15][17]. - Maintaining a healthy lifestyle, including diet and exercise, is crucial for preventing weight regain after discontinuation [17]. Group 6: Lifestyle Management - The latest guidelines emphasize that lifestyle interventions, including dietary management, exercise, and behavioral changes, are essential for long-term weight management [18]. - Various dietary patterns, such as low-calorie diets and intermittent fasting, can lead to weight loss, but individual adherence is critical for sustained results [19][21]. - Exercise contributes to long-term weight maintenance and improves overall quality of life, despite only achieving modest weight loss on its own [22]. Group 7: Importance of Continued Medication - Long-term use of semaglutide is necessary for effective weight management, as obesity is a chronic condition requiring ongoing treatment [25]. - Studies show that sustained use of semaglutide leads to significant weight loss and maintenance over extended periods, highlighting the importance of adherence to treatment [25].

Core Viewpoint - The recent announcement by the National Medical Products Administration regarding the revision of the isotretinoin capsule instructions has raised significant attention due to the addition of new risk warnings related to its side effects [1][3]. Group 1: Side Effects and Risks - The revised instructions for isotretinoin now include numerous potential adverse reactions, such as endocrine, digestive, mental, and reproductive issues, with specific warnings about depression, agitation, and rare cases of suicidal thoughts or attempts [3][4]. - Reports of sexual dysfunction associated with isotretinoin have emerged, with some patients experiencing long-term symptoms even after discontinuation of the drug, potentially requiring specialized treatment [3][4]. - Common side effects include dryness of the skin, lips, and mucous membranes, which are generally mild and manageable, with most symptoms resolving after stopping the medication [4][5]. Group 2: Clinical Use and Recommendations - Isotretinoin is primarily used for treating acne, particularly severe nodular acne, due to its ability to address multiple factors contributing to acne development [3][4]. - Treatment typically starts with a standard dose, which may be reduced as the condition improves, helping to minimize adverse reactions; the entire treatment cycle usually lasts several months [3][4]. - The prescribing of isotretinoin requires careful evaluation by healthcare professionals, especially for patients with a history of mental health issues, and alternative treatments may be recommended for mild cases [5].

Core Viewpoint - The article discusses a case where a patient experienced compulsive gambling behavior after taking a prescription drug called "Bromocriptine Mesylate Tablets," which is linked to rare side effects including pathological gambling [1] Group 1: Drug Information - Bromocriptine Mesylate Tablets are associated with impulsive control disorders, leading to an abnormal craving for high-risk, high-reward behaviors [1] - The occurrence of such side effects is extremely rare, with an incidence rate of less than 1 in 10,000 [1] Group 2: Patient Experience - A user reported that their compulsive gambling behavior ceased after discontinuing the medication, highlighting a direct correlation between the drug and the behavior [1] - The patient initially attributed their gambling behavior to the medication after reviewing the drug's side effects listed in the product information [1]

Core Viewpoint - The Danish pharmaceutical company Novo Nordisk's semaglutide drugs, Ozempic and Wegovy, are reported to potentially cause severe vision impairment, specifically a rare side effect known as NAION, leading to compensation claims from affected patients [2][5]. Group 1: Patient Compensation Claims - A total of 43 patients have filed compensation claims with the Danish Patient Compensation Association after experiencing NAION following the use of Ozempic or Wegovy [2]. - The association has ruled on the first five cases, granting compensation in four instances, while one case was dismissed [2]. - The total compensation amount for the four patients is approximately 800,000 Danish kroner (around 878,000 RMB), with potential increases if patients suffer income loss due to NAION [5]. Group 2: Nature of NAION - NAION is described as a serious condition affecting the front part of the optic nerve, potentially leading to permanent vision loss and field defects [1][5]. - The occurrence rate of NAION due to semaglutide is reported to be less than 0.01% [5]. Group 3: Regulatory Actions and Research - The Danish Medicines Agency issued a warning to the European Medicines Agency based on two large Danish studies indicating a link between semaglutide and NAION [5]. - The European Medicines Agency confirmed that NAION is a rare side effect of Wegovy, Ozempic, and Rybelsus [5]. Group 4: Patient Population and Side Effects - It is estimated that by the end of 2025, over 50 million people globally will have used semaglutide, with around 22-25 million for diabetes treatment and 16-18 million for weight loss [6]. - Common side effects of semaglutide include gastrointestinal reactions, while severe side effects can include acute pancreatitis and gallbladder disease [6].

Core Viewpoint - Novo Nordisk's weight loss drug semaglutide has been linked to severe vision damage, with 43 patients filing for compensation in Denmark due to a rare side effect known as NAION [1][4][5] Group 1: Patient Compensation and Legal Proceedings - The Danish Patient Compensation Association reported that 43 patients experienced severe eye disease NAION after using Ozempic or Wegovy, with initial rulings on five cases resulting in four compensations [1][2] - The total compensation for the four patients is approximately 800,000 Danish kroner (about 878,000 RMB), with potential increases if patients suffer income loss due to NAION [4] Group 2: Medical and Regulatory Insights - NAION is a serious condition affecting the optic nerve, potentially leading to vision loss and is considered a rare side effect of semaglutide-containing drugs [4][5] - The Danish Medicines Agency issued a warning based on two large studies indicating a link between NAION and semaglutide, with the European Medicines Agency confirming this association in June 2025 [4][5] Group 3: Market and Usage Statistics - Despite the low incidence rate of NAION (less than 0.01%), the large patient population using semaglutide raises concerns about other complications and side effects [5] - By the end of 2025, it is estimated that over 50 million people globally will have used semaglutide, with approximately 22-25 million for diabetes treatment and 16-18 million for weight loss [5]